Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
GermanyIPO:
07 November 2017Website:
http://www.inflarx.deNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 28 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
IFRX Latest News
JENA, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today hosted a virtual R&D event focused on the company's oral small molecule C5aR inhibitor, INF904. Speakers provided additional details on development rationales and plans for INF904, as well as additional insight into its potential role in CSU and HS and its broader therapeutic potential in the immuno-inflammation field.
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.20.
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company's anticipated development plans for INF904, InflaRx's orally available C5aR inhibitor with best-in-class potential. The Company will also publish its financial and operating results for the fourth quarter and full year 2023 on March 21, 2024, in advance of the call.
InflaRx N.V. (IFRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.
InflaRx N.V. (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
InflaRx N.V. (IFRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
InflaRx is a developer of complement mediated therapies for inflammatory diseases. Their lead asset, vilobelimab, is a C5a inhibitor targeting Pyoderma Gangraenosum in a phase 3 trial. The company has a cash runway of 7-8 quarters and raised $40mn in a public offering in April.
Shares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatment of critically ill COVID-19 patients.
InflaRx stock has soared on news that the company's Gohibic drug had received Emergency Use Authorization from the FDA. Analysts expect that Gohibic will be priced above $20,000 per treatment course.
The US Food and Drug Administration (FDA) granted emergency-use authorization (EUA) to InflaRx NV's monoclonal antibody for the treatment of hospitalized Covid-19 patients, sending the company's stock soaring. Shares of the German biopharmaceutical company skyrocketed nearly 60% to $6.02 on Wednesday.
What type of business is InflaRx NV?
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
What sector is InflaRx NV in?
InflaRx NV is in the Healthcare sector
What industry is InflaRx NV in?
InflaRx NV is in the Biotechnology industry
What country is InflaRx NV from?
InflaRx NV is headquartered in Germany
When did InflaRx NV go public?
InflaRx NV initial public offering (IPO) was on 07 November 2017
What is InflaRx NV website?
https://www.inflarx.de
Is InflaRx NV in the S&P 500?
No, InflaRx NV is not included in the S&P 500 index
Is InflaRx NV in the NASDAQ 100?
No, InflaRx NV is not included in the NASDAQ 100 index
Is InflaRx NV in the Dow Jones?
No, InflaRx NV is not included in the Dow Jones index
When does InflaRx NV report earnings?
The next expected earnings date for InflaRx NV is 09 August 2024